Pharmacoeconomic review report. Nusinersen (Spinraza) (Biogen Canada Inc.).
Spinal muscular atrophy (SMA) is a severe neuromuscular disease and is the leading genetic cause of infant death. It is characterized by the degeneration of alpha motor neurons in the anterior horn of the spinal cord, leading to progressive muscle weakness. The most common form of SMA, 5q SMA, makes...
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK534118/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2018
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
